New antibody injection targets Hard-to-Treat lung cancer in early trial

NCT ID NCT07260708

Recruiting now Disease control Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called TQB2922, given as a shot under the skin, in 42 people with advanced non-small cell lung cancer that has not responded to standard treatments. The drug is a bispecific antibody designed to block two cancer-related proteins (EGFR and c-Met). The main goal is to check safety and how the drug moves through the body, not yet to cure the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TQB2922 injection (a bispecific antibody targeting EGFR and c-Met proteins)
What this could lead to: If successful, this could point toward a new treatment option for advanced non-small cell lung cancer that has not responded to standard therapies.
What could go wrong: This is a very early Phase 1 trial with only 42 people, focused on safety and dosing. It is too small to prove effectiveness, and the drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED CANCERS

Contacts and locations

Locations

Affiliated Zhongshan Hospital of Dalian University
RECRUITING

Dalian, Liaoning, 116001, China
Chengdu Third People's Hospital
NOT_YET_RECRUITING

Chengdu, Sichuan, 610100, China
Henan Cancer Hospital
RECRUITING

Zhengzhou, Henan, 450003, China
Hunan Cancer Hospital
NOT_YET_RECRUITING

Changsha, Hunan, 410013, China
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210008, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, 250117, China
Shanghai Pulmonary Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200433, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Affiliated Hospital of Nanchang University
RECRUITING

Nanchang, Jiangxi, 330006, China
The First Affiliated Hospital of Zhengzhou University
NOT_YET_RECRUITING

Zhengzhou, Henan, 450052, China
West China hospital, Sichuan University
NOT_YET_RECRUITING

Chengdu, Sichuan, 610041, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.